Cancer Family
Head and Neck Neoplasm
CI-CAN-00000021Explore in graph →
Non-malignant1,572 active trials17 approved drugs142 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000021Explore in graph →
Clinical trials
6,373 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06019130 | Nivolumab in Children and Adults With Nasopharyngeal Carcinoma(NPC-Nivo) | recruiting | Phase 2 | 57 | German Society for Pediatric Oncology and Hematology GPOH gGmbHOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT03914378 | The Effects on Auditory Function of RADiotherapy and Chemotherapy Treatments for Head and Neck Tumours (EARAD)(EARAD) | recruiting | — | 100 | University of ManchesterOTHER |
| 1 |
| May 8, 2024 |
| clinicaltrials |
| NCT05727605 | Neurocognition After Radiotherapy in CNS- and Skull-base Tumors(NARCiS) | recruiting | N/A | 120 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06282497 | Xerostomia-optimised IMRT Versus Standard IMRT in NPC | recruiting | N/A | 524 | Zhongshan People's Hospital, Guangdong, ChinaOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT06151743 | Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma | recruiting | Phase 2 | 32 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT05659524 | Nasal Outcomes Using Saline Irrigations After Endonasal Pituitary Surgery(NOSE) | recruiting | N/A | 140 | Lori WoodOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT02435576 | Standard Follow-up Program (SFP) for Head and Neck Cancer Patients(H&NTOX) | recruiting | — | 10,000 | University Medical Center GroningenOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT06345287 | Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC | recruiting | Phase 2 | 133 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT05798793 | Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma(NEOPCOSCC) | recruiting | Phase 3 | 309 | Hospital of Stomatology, Wuhan UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06333587 | Minimally Invasive Treatments of the Thyroid(MIPA-MITT) | recruiting | — | 270 | European Institute of OncologyOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT05098119 | Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002) | recruiting | Phase 2 | 43 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT06265025 | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 125 | GeneMedicine Co., Ltd.INDUSTRY | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06321939 | Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma | recruiting | — | 50 | Hunan Cancer HospitalOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT06313450 | De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyngeal Carcinoma | recruiting | N/A | 112 | Sun Yat-sen UniversityOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT05280314 | Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors | recruiting | Phase 2 | 60 | IO BiotechINDUSTRY | 6 | Mar 18, 2024 | clinicaltrials |
| NCT02678884 | Head and Neck Squamous Cell Carcinoma (HNSCC)PET-CT Pilot Study | recruiting | N/A | 20 | University Health Network, TorontoOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT06307314 | Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis | recruiting | — | 300 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06248944 | AIOCC Italian Registry on Head and Neck Carcinomas | recruiting | — | 7,000 | Italian Head&Neck SocietyOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT04104945 | p16+ Oropharyngeal Cancer Radiation Optimization Trial Reducing Elective Treatment Volumes (PROTEcT)(PROTEcT) | recruiting | N/A | 32 | AHS Cancer Control AlbertaOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06291610 | Feasibility Testing a Decision-support Intervention for Clinical Trials | recruiting | N/A | 60 | University of AarhusOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06286631 | Prediction of Lymph Node Metastasis in Patients With Thyroid Malignancy by a New Scale | recruiting | — | 800 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT06277180 | 68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC | recruiting | N/A | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT03326947 | Phage II Trial of Stathmin as Predictive Biomarker for TPF Induction Chemotherapy in OSCC | recruiting | Phase 2 | 60 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06041555 | MRI Guided Radiotherapy and Radiobiological Data: the ISRAR Database (Irm Sequences for Radiobiological Adaptative Radiotherapy)(ISRAR) | recruiting | — | 600 | Hospices Civils de LyonOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06182657 | The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC | recruiting | — | 300 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05192655 | Artificial Intelligence in Functional Imaging for Individualized Treatment of Head and Neck Squamous Cell Carcinoma Patients(KIVAL-KHT) | recruiting | — | 250 | Charite University, Berlin, GermanyOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06240689 | A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood | recruiting | Phase 2 | 104 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT06241599 | A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) | recruiting | Phase 2 / Phase 3 | 300 | Sun Yat-sen UniversityOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT05952947 | HRYZ-T101 Injection for HPV18 Positive Solid Tumor | recruiting | Phase 1 | 32 | HRYZ Biotech Co.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT05962892 | A Study of Factors Influencing Recurrence After Thermal Ablation of Papillary Thyroid Carcinoma | recruiting | — | 600 | Beijing Friendship HospitalOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT06092957 | Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy | recruiting | Phase 3 | 504 | Sun Yat-sen UniversityOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT06170710 | Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC | recruiting | Phase 2 | 173 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT03908684 | Ultrasound Spectroscopy as Early Indicators of Radiation Treatment Response in Prostate, Rectum and Head & Neck Cancers | recruiting | — | 320 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT04428515 | Pilot Study to Evaluate Photoacoustic Imaging in Head and Neck Cancer | recruiting | — | 50 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT06167109 | NBI Combined With MRI to Guide CTV Optimization in Eccentric Nasopharyngeal Carcinoma | recruiting | N/A | 60 | Chongqing University Cancer HospitalOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT02139020 | Collection of Plasma Samples for Squamous Cell Carcinoma of the Head and Neck Patients | recruiting | — | 400 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Dec 11, 2023 | clinicaltrials |
| NCT04729543 | MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer(MC2TCR) | recruiting | Phase 1 / Phase 2 | 20 | Erasmus Medical CenterOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT04214366 | Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation(ACCO) | recruiting | Phase 2 | 314 | Heidelberg UniversityOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT02290145 | Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage | recruiting | Phase 2 | 48 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05069857 | Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients | recruiting | Phase 2 | 46 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05125055 | Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC | recruiting | Phase 2 / Phase 3 | 80 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06130332 | Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004) | recruiting | Phase 2 | 40 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 14, 2023 | clinicaltrials |
| NCT06116019 | Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)(ART-02) | recruiting | — | 649 | Charite University, Berlin, GermanyOTHER | 1 | Nov 3, 2023 | clinicaltrials |
| NCT06102395 | Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC | recruiting | Phase 3 | 272 | Beijing Tongren HospitalOTHER | 1 | Oct 30, 2023 | clinicaltrials |
| NCT05260671 | Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN | recruiting | Phase 2 | 48 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT06087068 | Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma | recruiting | Phase 2 | 140 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT06082180 | A Prospective, Open-label, Multicenter, Randomized Controlled Phase III Study of Prophylactic Central Neck Dissection in Low-risk Papillary Thyroid Cancer | recruiting | Phase 3 | 1,199 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT06079333 | NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)(NEO-ATACT) | recruiting | Phase 2 | 20 | Leiden University Medical CenterOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT05777824 | Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy(HN) | recruiting | Phase 2 | 84 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT05918510 | Observational Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx and Occult Tumors Positive for Papilloma Virus | recruiting | — | 142 | Regina Elena Cancer InstituteOTHER | 1 | Oct 10, 2023 | clinicaltrials |
Data updated 23 days agoSource updated May 16, 2024source: clinicaltrials